The Board of Directors at their meeting held today, 19th June 2025 has approved the proposal to raising of funds by way of issuance of equity shares and / or eligible securities through ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries' Board of Directors, at a meeting held on 19th June 2025, approved a proposal to raise funds up to ₹350 Crores (or equivalent in foreign currency). The funds may be raised through equity shares and a wide range of eligible securities, including Foreign Currency Convertible Bonds (FCCBs), fully/partly convertible debentures, non-convertible debentures with warrants, and other instruments convertible into equity shares. The company may use one or more routes — public issue, preferential issue, qualified institutions placement (QIP), private placement, or a combination — in domestic and/or international markets, in one or more tranches. The proposal is subject to approval from regulatory authorities and shareholders at a general meeting.
This is a potential dilution event for existing shareholders as the company plans to issue fresh equity-linked securities worth up to ₹350 Crores. The final impact on share price will depend on the issue price, structure, and timing. Short-term share price may face pressure depending on pricing relative to market price, though the capital infusion could support business growth if used productively.